STOCK TITAN

Onto Innovation (NYSE: ONTO) revises Semilab deal, sees EPS up approximately 10%

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Onto Innovation Inc. amended its agreement to acquire Semilab USA after a U.S. Department of Justice Second Request extended the antitrust review timeline. To help secure regulatory clearance, the parties agreed that Semilab’s Fourier-Transform infrared spectroscopy reflectometry systems business will be excluded from the deal and retained by the seller.

Under the amended terms, Onto Innovation will pay $432,310,000 in cash (subject to customary adjustments) and issue 641,771 shares of common stock, a reduction of approximately $50 million to approximately $495 million based on the Company’s June 27, 2025 share price. The excluded business represents approximately $13 million, or 10%, of estimated 2025 revenue for Semilab USA.

Onto Innovation expects the business it will acquire, excluding the carved-out operation, to generate approximately $120 million in annual revenue and to increase earnings per share by approximately 10% in the first year after closing. The company affirms its previously issued third quarter 2025 guidance and continues to anticipate completing the transaction in 2025, subject to Hart-Scott-Rodino clearance.

Positive

  • Amended Semilab USA acquisition is expected to generate approximately $120 million in annual revenue for Onto Innovation.
  • The company projects the revised transaction will increase earnings per share by approximately 10% in the first year after closing.
  • Onto Innovation affirms its third quarter 2025 guidance while continuing to anticipate closing the transaction in 2025.

Negative

  • A Department of Justice Second Request extends the Hart-Scott-Rodino waiting period and introduces regulatory timing uncertainty for closing.
  • To address regulatory concerns, Onto Innovation agreed to exclude a business representing approximately $13 million, or 10%, of Semilab USA’s estimated 2025 revenue, reducing the overall scope of the acquisition.

Insights

Onto revises Semilab deal to ease antitrust review while keeping EPS accretion.

Onto Innovation and the Semilab seller received a Department of Justice Second Request, which significantly extends the Hart-Scott-Rodino review. In response, they amended the transaction so the Fourier-Transform infrared spectroscopy reflectometry systems business stays with the seller, and will withdraw and refile their HSR notifications.

The amended consideration is $432,310,000 in cash plus 641,771 shares of Onto common stock, a reduction of approximately $50 million to approximately $495 million based on the June 27, 2025 share value. The excluded operation represents approximately $13 million, or 10%, of estimated 2025 Semilab USA revenue, while the remaining business is expected to produce approximately $120 million in annual revenue.

Onto states that the revised deal should still increase earnings per share by approximately 10% in the first year post-closing and affirms its third quarter 2025 guidance. The company continues to anticipate closing in 2025, but actual timing depends on expiration or termination of the HSR waiting period and outcomes of DOJ and FTC review.

0000704532false00007045322025-10-092025-10-09

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 09, 2025

 

 

Onto Innovation Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39110

94-2276314

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

16 Jonspin Road

 

Wilmington, Massachusetts

 

01887

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (978) 253-6200

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.001 par value per share

 

ONTO

 

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 1.01. Entry into a Material Definitive Agreement

As previously announced, on June 27, 2025, Onto Innovation Inc. (the “Company”) entered into an Equity Purchase Agreement (the “Purchase Agreement”) with Semilab International Zrt. (the “Seller”), Semilab Zrt. and Semilab USA LLC (“Semilab USA”), pursuant to which the Company agreed to acquire all of the outstanding membership interests of Semilab USA from the Seller (the “Transaction”), subject to the satisfaction of customary closing conditions, including the expiration or termination of any waiting period applicable under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), and receipt of Hungarian foreign direct investment approval. Hungarian foreign direct investment approval was received in September 2025.

On September 25, 2025, each of the Company and the Seller received a request for additional information and documentary material (a “Second Request”) from the U.S. Department of Justice (the “DOJ”) in connection with the Transaction. The Second Request extends the waiting period imposed by the HSR Act to 30 days after the Company and the Seller have substantially complied with the Second Request, which could take a significant amount of time.

In response to the Second Request, and in order to increase the likelihood of a timely closing for the Transaction, on October 9, 2025, the parties entered into an amendment to the Purchase Agreement (the “Purchase Agreement Amendment”), pursuant to which the parties agreed that the Fourier-Transform infrared spectroscopy reflectometry systems business conducted by the Seller and its affiliates (the “EIR Business”) would not be included in the Transaction and would instead be retained by the Seller. The Purchase Agreement Amendment amends the purchase price that the Company will pay to the Seller in the Transaction to $432,310,000 in cash (subject to certain customary purchase price adjustments) and 641,771 shares of the Company’s common stock, par value $0.001 per share. This represents a reduction of approximately $50 million in purchase price to approximately $495 million based upon the closing value of the Company’s common stock on June 27, 2025.

The Company and the Seller intend to withdraw their existing HSR Act filings with the DOJ, and submit a notification and report form with the DOJ and the Federal Trade Commission (the “FTC”) with respect to the Transaction as amended pursuant to the Purchase Agreement Amendment. Closing of the Transaction is subject to the expiration or termination of any waiting period applicable under the HSR Act, and the Company and the Seller intend to continue working cooperatively with the DOJ and/or the FTC to obtain regulatory clearance for the Transaction as expeditiously as possible.

The foregoing description of the Purchase Agreement Amendment is qualified entirely by reference to the full text of the Purchase Agreement Amendment, a copy of which is filed as Exhibit 2.1 to this Current Report on Form 8-K and incorporated herein by reference.

The Purchase Agreement Amendment has been attached to provide investors with information regarding its terms. It is not intended to provide any other factual information about the Company, Semilab USA, their respective subsidiaries or any of the other parties to the Purchase Agreement Amendment or any related documents.

Item 7.01. Regulation FD Disclosure

The EIR Business represents approximately $13 million, or 10%, of estimated 2025 revenue for Semilab USA. The Company expects that the business to be acquired, excluding the EIR Business, pursuant to the amended Transaction will generate approximately $120 million in annual revenue and will increase earnings per share by approximately 10% in the first year following the close of the transaction. Additionally, the Company affirms its third quarter guidance, initially provided on August 7, 2025.

The Company continues to anticipate that the Transaction will be completed in 2025.

The information contained in Item 7.01 of this Current Report on Form 8-K shall be deemed furnished and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation by reference language in such filing, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description of Exhibit

2.1*

Amendment to Equity Purchase Agreement, dated as of October 9, 2025, by and among Onto Innovation Inc., Semilab USA LLC, Semilab International Zrt. and Semilab Zrt.*

104

Cover Page Interaction Data File (embedded within the Inline XBRL document)

 

*

Schedules omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request.

 


CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act”) which include statements relating to its projected financial performance and the projected financial performance of the acquired business; the Company’s business momentum and future growth; the benefit to customers and the capabilities of the Company’s products and customer service; the Company’s ability to both deliver products and services consistent with our customers’ demands and expectations and strengthen its market position, the Company’s beliefs about market opportunities, the timing and ability of the Company to complete the Transaction, the benefits of the Transaction to the Company, its stockholders and its customers, as well as other matters that are not purely historical data. The Company wishes to take advantage of the “safe harbor” provided for by the Act and cautions investors not to place undue reliance on any forward-looking statements and that actual results may differ materially from those projected as a result of various factors, including risks and uncertainties, many of which are beyond the Company’s control. Such factors include, but are not limited to, one or more closing conditions to the Transaction, including certain regulatory approvals, may not be satisfied or waived, on a timely basis or otherwise, including that a governmental entity may prohibit, delay, or refuse to grant approval for the consummation of the proposed Transaction, or may require conditions, limitations, or restrictions in connection with such approvals; the risk that the Transaction may not be completed in the time frame expected by the Company, or at all; unexpected costs, charges, or expenses resulting from the Transaction; failure to realize the anticipated benefits of the Transaction, including as a result of delay in completing the Transaction or integrating the acquired business with the business of the Company; difficulties and delays in achieving revenue and cost synergies anticipated to be realized from the Transaction; the occurrence of any event that could give rise to termination of the Transaction; evolving legal, regulatory, and tax regimes; changes in economic, financial, political, and regulatory conditions, in the United States and elsewhere, and other factors that contribute to uncertainty and volatility, natural and man-made disasters, civil unrest, pandemics, geopolitical uncertainty, and conditions that may result from legislative, regulatory, trade, and policy changes; risks related to disruption of management time from ongoing business operations due to the Transaction; the risk that the Transaction and its announcement could have an adverse effect on the ability of the Company or the acquired business to retain customers and retain and hire key personnel and maintain relationships with customers, suppliers, employees, stockholders, strategic partners and other business relationships and on their operating results and business generally; the Company’s ability to deploy its resources to improve its position in its core markets; its ability to weather difficult economic environments; its ability to open new market opportunities and target high-margin markets; the strength/weakness of the back-end and/or front-end semiconductor market segments; fluctuations in customer capital spending; the Company’s ability to effectively manage its supply chain and adequately source components from suppliers to meet customer demand; its ability to adequately protect its intellectual property rights and maintain data security; its ability to effectively maneuver global trade issues and changes in trade and export license policies; the Company’s ability to maintain relationships with its customers and manage appropriate levels of inventory to meet customer demands; and the Company’s ability to successfully integrate acquired businesses and technologies. Additional information and considerations regarding the risks faced by the Company are available in the Company’s Annual Report on Form 10-K for the year ended December 28, 2024, and other filings with the Securities and Exchange Commission. As the forward-looking statements are based on the Company’s current expectations, the Company cannot guarantee any related future results, levels of activity, performance or achievements. The Company does not assume any obligation to update the forward-looking information contained in this Current Report on Form 8-K, except as required by law. Neither future distribution of this Current Report on Form 8-K nor the continued availability of this Current Report on Form 8-K should be deemed to constitute an update or re-affirmation of these statements as of any future date.

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Onto Innovation Inc.

 

 

 

 

Date:

October 10, 2025

By:

/s/ Yoon Ah Oh

 

 

 

Senior Vice President, General Counsel & Corporate Secretary

 


FAQ

What transaction did Onto Innovation (ONTO) amend with Semilab USA?

Onto Innovation amended its Equity Purchase Agreement to acquire all membership interests of Semilab USA, excluding the Fourier-Transform infrared spectroscopy reflectometry systems business, which will be retained by the seller.

How did the Onto Innovation (ONTO) purchase price change in the amended Semilab deal?

The amended consideration is $432,310,000 in cash (subject to customary adjustments) plus 641,771 Onto Innovation shares, representing a reduction of approximately $50 million to approximately $495 million based on the June 27, 2025 share value.

Why did Onto Innovation (ONTO) revise its Semilab USA acquisition structure?

After receiving a Department of Justice Second Request under the Hart-Scott-Rodino Act, the parties excluded the Fourier-Transform infrared spectroscopy reflectometry systems business from the transaction to increase the likelihood of a timely closing and plan to withdraw and refile their HSR submissions.

What part of Semilab USA’s revenue is excluded from the Onto Innovation (ONTO) deal?

The excluded Fourier-Transform infrared spectroscopy reflectometry systems business represents approximately $13 million, or 10%, of estimated 2025 revenue for Semilab USA.

What revenue and earnings impact does Onto Innovation (ONTO) expect from the amended Semilab acquisition?

Onto Innovation expects the acquired business, excluding the carved-out operation, to generate approximately $120 million in annual revenue and to increase earnings per share by approximately 10% in the first year after closing.

Does Onto Innovation (ONTO) still expect the Semilab transaction to close in 2025?

Yes. Onto Innovation states that it continues to anticipate completing the transaction in 2025, subject to expiration or termination of the Hart-Scott-Rodino waiting period and regulatory clearance.

Did Onto Innovation (ONTO) change its third quarter 2025 guidance in connection with the amended deal?

No. Onto Innovation explicitly affirms its third quarter 2025 guidance that was initially provided on August 7, 2025.
Onto Innovation Inc

NYSE:ONTO

ONTO Rankings

ONTO Latest News

ONTO Latest SEC Filings

ONTO Stock Data

10.58B
49.30M
0.79%
102.46%
4.2%
Semiconductor Equipment & Materials
Measuring & Controlling Devices, Nec
Link
United States
WILMINGTON